medigraphic.com
ISSN 1405-8871 (Print)

2013, Number 4

<< Back Next >>

Aten Fam 2013; 20 (4)

Anti-microbial for the Irritable Bowel Syndrome?

Frati-Munari AC

Language: Spanish
References: 33
Page: 123-126
PDF size: 339.39 Kb.


ABSTRACT

The Irritable Bowel Syndrome (IBS) is a chronic functional disorder of the digestive tract which courses with discomfort or abdominal pain, diarrhea or constipation, bloating and other intestinal symptoms. Although a unique cause of ibs is unknown, recently it has been emphasized the participation of the bacteria in its pathophysiology, especially by the presentation of the IBSibs after gastrointestinal infections. The presence of bacterial overgrowth in the small intestine and changes of the intestinal micro-biota may cause intestinal micro-inflammation, alterations of intestinal motility, visceral hypersensitivity and excessive production of gas, which would be the cause of the symptoms. A longer clinical response after the use of non absorbable antibiotics of wide spectrum, especially rifaximina, supports the concept and provides an additional treatment for many patients.


REFERENCES

  1. Remes-Troche JA. Actualidades en la fisiopatología del síndrome de intestino irritable: el papel de las infecciones. Med Int Mex. 2012;28:461-72.

  2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-91.

  3. López Colombo A, Rivera Ramos JF, Sobrino Cossio S, Suárez Morán E. Guías clínicas de diagnóstico y tratamiento en gastroenterología del síndrome de intestino irritable. Epidemiología y fisiopatología. Rev Gastroenterol Mex. 2009;74:56-7.

  4. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel síndrome: a five-year prospective study. Lancet. 1987;1:963-5.

  5. Thabane M, Kottachchi DT, Marshal JK. Systematic review and meta-analysis: the incidence and prognosis of postinfectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535-44.

  6. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, et al. Eight year prognosis of postinfectious irritable bowel síndrome following waterborne bacterial dysentery. Gut. 2010;59:605-11.

  7. Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga AM, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107:891-9.

  8. Pimentel M, Morales W, Jee SR, Low K, Hwang L, Pokkunuri V, et al. Antibiotic prophylaxis prevents the development of a new rat model of post-infectious ibs. Dig Dis Sci. 2011;56:1962-6.

  9. Mearin F. Síndrome de intestino irritable: nuevos criterios Roma iii. Med Clin (Barc). 2007;128:335-43.

  10. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota T, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157-60.

  11. Jeffrey IB, O’Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012; 61:997-1006.

  12. Lee KJ, Tack J. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:493-8.

  13. Kings TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel síndrome. Lancet. 1998;352:1187-9.

  14. Koide A, Yamaguchi T, Odaka T, Koyama H, Tsuyuguchi T, Kitahara H, et al. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel síndrome. Am J Gastroenterol. 2000;95:1735-41.

  15. Stotzer PO, Björnsson ES, Abrahamsson H. Interdigestive and postprandial motility in small intestinal bacteria overgrowth. Scand J Gastroenterol. 1998;31:875-80.

  16. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of mmc is found in ibs subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639-43.

  17. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;66:802-8.

  18. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693-702.

  19. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, et al. Review article: associations between immune activation, intestinal permeability and irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36:1009-31.

  20. Gasbarrini A, Lauritano EC, Garcovich M, Sparano L, Gasbarrini G. New insights into the pathophysiology of ibs: intestinal microflora, gas production and gut motility. Eur Rev Pharmacol Sci. 2008;12(Suppl 1):111-7.

  21. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31-5.

  22. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidan S, ElHajj I. A randomized doublé-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-33.

  23. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551-6.

  24. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptoms improvement in irritable bowel syndrome. A double-blind, randomized, placebo controlled study. Am J Gastroenterol. 2003;98:412-9.

  25. Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, et al. Antibiotic therapy in small intestine bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13:111-6.

  26. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of irritable bowel síndrome: a randomized trial. Ann Intern Med. 2006;145:557-63.

  27. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaxim therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.

  28. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28-35.

  29. Pimentel M, Morales W, Chua K, Barlow G, Weitsman S, Kim G, et al. Effects of rifaximin treatment and retreatment in nonconstipated ibs subjects. Dig Dis Sci. 2011;56:2067-72.

  30. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetc properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467-84.

  31. Remes-Troche JM, Gómez-Escudero O, Nogueira-de Rojas JR, Carmona-Sánchez R, Pérez-Manauta J, López-Colombo A, et al. Tratamiento farmacológico del síndrome de intestino irritable: revisión técnica. Rev Gastroenterol Mex. 2010;75:42-66.

  32. Schmulson MJ, Noble Lugo A, Valenzuela de la Cueva VM, De Ariño Suárez M, Guillermo Denis LAJ, Ramos Narváez FA. Guías clínicas de diagnóstico y tratamiento en gastroenterología del síndrome de intestino irritable. Tratamiento. Rev Gastroenterol Mex. 2009;74:63-70.

  33. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, et al. The American College of Gastroenterology ibs Task Force. Am J Gastroenterol. 2009;104:S1-S35.




2020     |     www.medigraphic.com